We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Erlotinib and Metformin in Triple Negative Breast Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01650506
First Posted: July 26, 2012
Last Update Posted: August 30, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Susan G. Komen Breast Cancer Foundation
Astellas Pharma Inc
Information provided by (Responsible Party):
Kevin Kalinsky, Columbia University
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: June 2016
  Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)